Overdosing on chemo: A common gene test could save hundreds of lives each year
A recent survey found that only 3% of U.S. oncologists routinely order the tests before dosing patients.
Stay updated with breaking news from Daniel Hertz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A recent survey found that only 3% of U.S. oncologists routinely order the tests before dosing patients.
A recent survey found that only 3% of U.S. oncologists routinely order the tests before dosing patients.
A recent survey found that only 3% of U.S. oncologists routinely order the tests before dosing patients.
US health experts have sounded the alarm about hundreds of cancer patients dying preventable deaths due to a lethal side effect of chemotherapy treatment, causing them to effectively overdose.
Patients with variants in the DPYD gene have an increased risk of severe toxicity and death from fluoropyrimidine chemotherapy, but many US cancer patients are not being tested for DPYD variants. Fluoropyrimidine chemotherapy kills more than 275,000 US cancer patients each year, but routine genetic testing could change that.